ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

Varenicline for smoking cessation: A placebo-controlled, randomized study

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : Varenicline for smoking cessation: A placebo-controlled, randomized study
นักวิจัย : Wang C. , Xiao D. , Chan K.P.W. , Pothirat C. , Garza D. , Davies S.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2552
อ้างอิง : 13237799 , 10.1111/j.1440-1843.2008.01476.x , 19192221 , RSPIF , http://www.scopus.com/inward/record.url?eid=2-s2.0-63849201453&partnerID=40&md5=7f76200f917f9424248ddfe542380ec8 , http://cmuir.cmu.ac.th/handle/6653943832/2874
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Background and objective: Varenicline tartrate, a novel, selective, nicotinic acetylcholine receptor partial agonist, has been developed specifically as a smoking cessation drug. This study evaluated the efficacy of a standard regimen of varenicline compared with placebo for smoking cessation in 333 subjects in China, Singapore and Thailand. Methods: This 24-week, randomized, double-blind, placebo-controlled trial of varenicline, 1 mg bd, consisted of a 12-week treatment period followed by a 12-week non-treatment follow-up period. The primary study end-point was the 4-week continuous abstinence rate defined as the proportion of subjects who reported total abstinence from smoking and other nicotine products from weeks 9-12. A key secondary end-point was the continuous abstinence rate from weeks 9-24, defined as the proportion of subjects who achieved the primary end-point as well as total abstinence from all tobacco products from weeks 13-24. Results: Both end-points were achieved by a significantly higher proportion of subjects in the varenicline group than in the placebo group. The 4-week continuous abstinence end-point was achieved by 50.3% and 31.6% in the varenicline and placebo groups, respectively (P = 0.0003), while continuous abstinence from weeks 9-24 was achieved by 38.2% and 25.0% of subjects, respectively (P = 0.0080). The treatment effect was generalizable by treatment centre and country. Varenicline was safe and appeared to be well tolerated by most subjects. Conclusion: Varenicline was significantly more efficacious for smoking cessation than placebo over a 12-week treatment period and a further 12-week non-treatment follow-up period in smokers from China, Singapore and Thailand. No significant side-effects were noted. © 2009 Asian Pacific Society of Respirology.

บรรณานุกรม :
Wang C. , Xiao D. , Chan K.P.W. , Pothirat C. , Garza D. , Davies S. . (2552). Varenicline for smoking cessation: A placebo-controlled, randomized study.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Wang C. , Xiao D. , Chan K.P.W. , Pothirat C. , Garza D. , Davies S. . 2552. "Varenicline for smoking cessation: A placebo-controlled, randomized study".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Wang C. , Xiao D. , Chan K.P.W. , Pothirat C. , Garza D. , Davies S. . "Varenicline for smoking cessation: A placebo-controlled, randomized study."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2552. Print.
Wang C. , Xiao D. , Chan K.P.W. , Pothirat C. , Garza D. , Davies S. . Varenicline for smoking cessation: A placebo-controlled, randomized study. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2552.